CalciMedica Inc CALC

Healthcare

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

NDAQ:CALC - Post by User

CalciMedica Inc

<< Previous

Bullboard Posts

Next >>

Post by alphaflighton Sep 23, 2021 9:41am

644 Views

Post# 33904269

Graycliff Expands Near Surface High-Grade Interval in Hole 9

Graycliff Exploration Expands Near Surface

High-Grade Interval in Hole 9 to

13.32 g/t Gold Over 16.0 Metres

TORONTO, ON – September 23, 2021 - Graycliff Exploration Limited (the “Company” or “Graycliff”) (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) is pleased to announce expanded (full) assay results on the previously announced second drill hole of its over 2,000 metre (“m”) phase two core drilling program on the Company’s Shakespeare Gold Project located on the prolific Canadian Shield near Sudbury, Ontario.

Drill Hole J-9-21 intersected a mineralized interval of 13.32 g/t gold (“Au”) over 16.0 metres, including the previously announced interval of 52.0 g/t Au over 4.0 m (see Press Release dated June 15, 2021), as detailed below:

Table 1 - Highlighted Results from Hole J-9-21

President and CEO, James Macintosh stated: “The second hole of phase two drilling has returned a second extended intersection of mineralization with very strong gold grades throughout and provides further evidence that we are in one larger zone as mentioned when we announced the results of Hole J-8-21. Hole J-9-21 also shows us that the higher-grade mineralized zone flanked by lower-grade mineralization that we would look to include in any potential mining scenario in the future. It is important to note that highest grade intersection in Hole J-9-21 is below the depth of the historic mine workings.”

Qualified Person

Bruce Durham, P.Geo, is a Qualified Person, as that term is defined by Canadian regulatory guidelines under NI 43-101, and has read and approved the technical information contained in this press release.

About Graycliff Exploration Limited.

Graycliff Exploration is a mineral exploration company focused on its 1,025 hectares of prospective ground, located roughly 80 kilometres west of Sudbury on the prolific Canadian Shield. The Company's Shakespeare Project consists of one crown patented lease, two crown leases and 40 claims on a property associated with the historic Shakespeare Gold Mine, which operated from 1903 to 1907. Graycliff’s Baldwin Project is adjacent to the east and is comprised of 68 claims covering 1,500 hectares. This brings our total land package in the area to 2,525 hectares.